[Therapy study of chronic polyarthritis with sulfasalazine with special emphasis on the profile of side effects].
138 patients, suffering from rheumatoid arthritis, were treated with sulfasalazine for up to 43 months. In 58.7% of the patients a good or moderate effect was ascertained. Side-effects occurred in 40.5% of the treated patients, mostly in the first 4 months after starting treatment, but some of the more serious adverse reactions occurred some months later. Presumably, drug-induced antinuclear antibodies were found in 29%, using Hep II cells and crithidia-luciliae flagellates. A lupus-like syndrome was not seen. Close controls of laboratory parameters are necessary including determination of liver enzyme levels a renal test, and blood counts according to the investigations in gold treatment. Detection of abnormal immunological reactions should be carefully scrutinized.
Lonauer
G
G
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012217:Rheumatoid Factor / Q000032:analysis; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects*
D012460:Sulfasalazine; D012217:Rheumatoid Factor
Therapiestudie der chronischen Polyarthritis mit Sulphasalazin unter dem besonderen Aspekt des Nebenwirkungsprofils.